Fig. 3: Kaplan–Meier analysis of EFS and DRFS stratified by ctDNA detection status at different timepoints in TNBC patients. | Nature Communications

Fig. 3: Kaplan–Meier analysis of EFS and DRFS stratified by ctDNA detection status at different timepoints in TNBC patients.

From: Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy

Fig. 3: Kaplan–Meier analysis of EFS and DRFS stratified by ctDNA detection status at different timepoints in TNBC patients.The alternative text for this image may have been generated using AI.

EFS (A) and DRFS (B) of 122 patients grouped by baseline ctDNA status. EFS (C) and DRFS (D) of 113 patients grouped by post-NAC (pre-surgery) ctDNA status. EFS (E) and DRFS (F) of 118 patients grouped by post-surgery ctDNA status. Survival analyses were performed using the Kaplan–Meier method. p values were calculated using the log-rank test. Hazard ratios (HR) and the corresponding confidence intervals (CI) were calculated using the Cox regression models. EFS event-free survival, DRFS distant recurrence-free survival. Source data are provided as a Source Data file.

Back to article page